An Introduction to NRG Oncology

Slides:

Advertisements

Similar presentations

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Advertisements

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

Algorithms used in heterogeneous dose calculations show systematic error as measured with the Radiological Physics Center’s anthropomorphic thorax phantom.

LAPS Grant Update Anthony Elias, MD PI 2/12/15. Background of Grant Much of SOC determined by NCTN trials Reconfiguring of NCTN by NCI due to declining.

Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD Moderator: John Bartlett, MD Discussants: Cal Cohen, MD.

International Clinical Trials Dr. Luis A. Salicrup Senior International Cancer Research Specialist Center for Global Health National Cancer Institute National.

2014. Diamond Members  Alexion  Bristol Myers Squibb  Cardinal Health  Eisai, Inc.  Foundation Medicine  Genomic Health  McKesson  MedImmune.

Carl-Wilhelm Vogel, MD, PhD Director. Financial Conflict of Interest Disclosure Incode Biopharmaceutics, Inc.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

1 Targeted Strategies to Improve Physician and Patient Access to Cancer Clinical Research An Overview of Coalition Programs and Services Ruth Lambersky.

Individualizing Care in HIV: A Critical Review of Treatment Options Presented by The Johns Hopkins University School of Medicine Produced in collaboration.

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.

CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

NFBIO: Update on NCI Imaging Activities Daniel C. Sullivan, M.D. Cancer Imaging Program, DCTD, NCI.

Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.

IN-1 Oncologic Drugs Advisory Committee Bethesda, Maryland January 31, 2002 C.

Building a Research Core Road Map and Lessons Learned Scott A. LeMaire, MD Professor of Surgery and of Molecular Physiology and Biophysics Vice Chair for.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

NJMS-UH Cancer Center Minority- Based Community Clinical Oncology Program.

NCCCP Pilot – Clinical Trials Ann O’Mara, PhD, RN, FAAN Program Director Community Clinical Oncology Program Division of Cancer Prevention June 26, 2007.

Global Autoimmune Drugs Market WEBSITE Single User License: US$ 2500 No of Pages: 137 Corporate User License: US$ 4000.

11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.

Browse more Reports on Cancer therapeutics at therapeuticshttp://

DIA DRM SIAC Content Re-Use Working Group March 22, 2012 Presenter:Sheila Jewels Strategy Consultant Virtify, Inc.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

CCO Independent Conference Highlights

FACULTY/PRESENTER DISCLOSURE

CCO Independent Conference Highlights

Miami Community Health Survey: Access to Care and

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

School-Based Health Programs What is the Role for Local

The Austin Health Experience

COI Disclosure Name of First Author

Oncology Grand Rounds “Potentially Lethal Prostate Cancer:

Evaluating Quality in Clinical Cancer Research: The M. D

Pathways in Anticoagulation

Relevant Financial Disclosure(s)

The Japan Diabetes Society

Chairs Sven Mahner (Germany) Antonio González-Martín (Spain)

The Role of the Statistician in Protocol Development

with regard to our presentation.

The Japanese Society for Helicobacter Research COI

Gynecologic Cancer Committee Clinical Trial Development

Clinical Trial Development: RA’s Role, OEWG, and IRB Submissions Martha Heckel Protocol Associate, ACRIN Dept. of Protocol Development & Regulatory.

NRG Oncology Biospecimen Bank Report NRG Semiannual meeting

Twitter 101 NRG SoMe Workshop

COI Disclosure STRUCTURE CLUB JAPAN Name of First Author

Toxicity Reporting in CAR-T

Nancy C. Cutter, MD, PT, Dan D. Scott, MD, Jane C

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Clinical Trial Development: NRG Processes and NCI Requirements

COI Disclosure Japan Diabetes Society

Treatment of Colorectal Cancer

The Japan Diabetes Society

Caso Clínico Enrique Grande Head of Medical Oncology

Anticipated Activation

TITLE & AUTHORS Presenter Name, Institution, Country.

OUHSC research programs are based principally at the Oklahoma City campus OUHSC Total Sponsored Awards.

Financial Disclosure Financial Interest / Affiliation

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development.

Andrew Merron Executive Director, Oncology & Biosimilars

Joan L. Walker, M.D. Stephenson Cancer Center University of Oklahoma

Patient Engagement through Social Media for Clinical Trials

Clinical Trial Development: NRG Processes and NCI Requirements

The Japanese Society for Helicobacter Research COI

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

An Introduction to NRG Oncology Angeles Alvarez Secord, MD, MHSc NRG Oncology Semi-Annual Meeting Phoenix Arizona February 8, 2019

Disclosures Clinical Trial Grants Advisory Boards AbbVie, Amgen, Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim, BMS, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Prima, Biomed, Roche/Genentech, TapImmune and TESARO. Advisory Boards Alexion, Aravive, Astex, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Merck, Mersana, Myriad, Oncoquest, Roche/Genentechand TESARO

Objectives 1. Define the different processes within NRG Oncology at each phase in the lifespan of a clinical trial. 2. Utilize the NCI Cancer Therapy Evaluation Program (CTEP) Project Team Member Applications (PTMA) 3. To develop a strategy to use NRG Oncology study data for ancillary projects

Agenda Nancy Soto, Director - NRG Oncology Protocol Development Process Mike Sill, PhD - The Role of the Statistician in Protocol Development and Study Design Carol Aghajanian, MD – Project Team Member Applications: Understanding PTMA Steven Waggoner, MD – NRG Oncology Study Data for Ancillary Projects ** Please remember to complete your evaluations**